Kadmon (NYSE:KDMN) Earns Buy Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Kadmon (NYSE:KDMN) in a research note issued to investors on Sunday, AnalystRatings.com reports. HC Wainwright currently has a $25.00 price target on the stock.

KDMN has been the subject of a number of other reports. Oppenheimer reaffirmed a buy rating and issued a $8.00 price objective on shares of Kadmon in a research note on Thursday, May 7th. ValuEngine raised Kadmon from a hold rating to a buy rating in a research note on Thursday, April 2nd. Raymond James began coverage on Kadmon in a research note on Tuesday, May 19th. They issued an outperform rating and a $7.00 price objective for the company. Finally, Zacks Investment Research upgraded Kadmon from a hold rating to a buy rating and set a $5.25 target price for the company in a report on Thursday, June 4th. Seven research analysts have rated the stock with a buy rating, Kadmon presently has a consensus rating of Buy and a consensus price target of $10.88.

KDMN stock opened at $5.17 on Friday. Kadmon has a 52-week low of $1.98 and a 52-week high of $5.50. The company has a quick ratio of 6.40, a current ratio of 6.42 and a debt-to-equity ratio of 0.20. The business has a fifty day moving average of $4.64 and a two-hundred day moving average of $4.43. The stock has a market cap of $812.95 million, a price-to-earnings ratio of -7.39 and a beta of 1.47.

Kadmon (NYSE:KDMN) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.19) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.14) by ($0.05). Kadmon had a negative net margin of 813.33% and a negative return on equity of 142.79%. The firm had revenue of $6.74 million during the quarter, compared to analyst estimates of $0.38 million. As a group, sell-side analysts anticipate that Kadmon will post -0.61 EPS for the current year.

Large investors have recently added to or reduced their stakes in the stock. Vivo Capital LLC purchased a new stake in Kadmon during the 1st quarter worth about $52,541,000. Boxer Capital LLC lifted its holdings in Kadmon by 55.1% during the 4th quarter. Boxer Capital LLC now owns 6,205,882 shares of the company’s stock worth $28,113,000 after buying an additional 2,205,882 shares during the last quarter. Avidity Partners Management LP lifted its holdings in Kadmon by 240.7% during the 1st quarter. Avidity Partners Management LP now owns 2,828,000 shares of the company’s stock worth $11,849,000 after buying an additional 1,998,000 shares during the last quarter. Perceptive Advisors LLC lifted its holdings in Kadmon by 11.2% during the 4th quarter. Perceptive Advisors LLC now owns 14,636,334 shares of the company’s stock worth $66,302,000 after buying an additional 1,470,588 shares during the last quarter. Finally, BlackRock Inc. lifted its holdings in Kadmon by 12.9% during the 1st quarter. BlackRock Inc. now owns 12,037,336 shares of the company’s stock worth $50,436,000 after buying an additional 1,374,003 shares during the last quarter. Hedge funds and other institutional investors own 85.64% of the company’s stock.

About Kadmon

Kadmon Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. The company markets and distributes products in various therapeutic areas, including ribavirin products for chronic hepatitis C virus infection; and distributes products in various therapeutic areas, including tetrabenazine for the treatment of chorea associated with Huntington's disease.

Read More: What is a balanced fund?

Analyst Recommendations for Kadmon (NYSE:KDMN)

Receive News & Ratings for Kadmon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon and related companies with MarketBeat.com's FREE daily email newsletter.